Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Perioperative oral dietary supplements before elective surgery offers no functional benefit

Blood glucose levels in a lot of patients fed normal liquid food (NLF) and a high calorie diet (HCD) were high. There was no significant difference in the blood prealbumin levels. There was a significant increase in the blood cortisol levels in some patients. The stress of surgery may be tolerated by children by feeding up to 2 h before elective surgery.

29 Oct 2009

Study: Short-term use of COX-2 inhibitors may help prevent gastric cancer

Elevated expression of COX-2 is observed in a wide variety of human malignancies, including gastric cancer. Long-term high dose COX-2 inhibitors can inhibit gastric carcinogenesis in animal models, but the possible life-threatening cardiovascular adverse events limit its popular application. Therefore, it is important to evaluate the optimal intervention point of COX-2 inhibitors for inhibiting H. pylori-associated gastric carcinogenesis.

29 Oct 2009

Lifestyle and genetic factors are considered to play a major role in "Asian paradox"

Although Helicobacter pylori (H. pylori) has been classified as a class I (or definite) carcinogen by World Health Organization (WHO), the controversy as to why only a minority of infected patients develop gastric cancer still remains. Moreover, in Asian countries such as Indonesia, Japan, China, and Thailand, where the H. pylori infection rates are similar, there is a significant difference regarding the outcome of gastric cancer. That fact has been termed the "Asian paradox".

29 Oct 2009

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

28 Oct 2009

Data from Phase II clinical trial of NKTR-118 presented

Data from a phase II study demonstrated that oral NKTR-118 improved lower gastrointestinal dysfunction by increasing the frequency of bowel movements in patients with opioid-induced constipation, while simultaneously preserving opioid-mediated analgesia.

28 Oct 2009

Eli Lilly receives access to GeneNews' osteoarthritis genomic biomarker program

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has entered into an agreement allowing Eli Lilly and Company (NYSE: LLY) select access to research from its osteoarthritis genomic biomarker program

27 Oct 2009

Studies highlight race- and gender-specific disparities in gastrointestinal disease

Three studies presented this week at the American College of Gastroenterology's 74th Annual Scientific meeting in San Diego underscore the growing disparities in gastrointestinal disease, particularly colon cancer and Barrett's Esophagus, among certain ethnic and gender populations, including African Americans, Latinos and women. These race- and gender-specific disparities underscore the need for education and vigilance among these populations and perhaps more aggressive screening tactics than the population in general.

27 Oct 2009

Colonoscopy recommended as primary screening method for colorectal cancer, researchers report

Researchers from Taiwan report in a new study that unsedated colonoscopy for primary colorectal cancer screening is well accepted in a majority of patients. Sedation is typically used for colonoscopy to make the patient feel comfortable during the procedure.

27 Oct 2009

Some colonoscopic technologies better at improving detection of adenomas

Recent advances in colonoscopic technology are featured in a number of studies presented at the Annual Scientific Meeting of the American College of Gastroenterology this week. In this research some technologies fare better than others at improving detection of potentially pre-cancerous growths in the colon known as adenomas.

27 Oct 2009

Comprehensive, risk-based screening guidelines for breast, cervical and colorectal cancers

Drawing on years of experience in cancer research and patient care, The University of Texas M. D. Anderson Cancer Center released today the most comprehensive, risk-based screening guidelines publicly available to date for breast, cervical and colorectal cancers.

27 Oct 2009

Clinical trial helps improve prognosis and changes the standard of care for patients with colorectal cancer

In a review article published this month in The Oncologist, UNC's Dr. Richard M. Goldberg and a team of colleagues catalogue how the data collected in a single large comparative clinical trial testing combination chemotherapy for metastatic colorectal cancer has been used not only to benefit the patients that enrolled but also patients who subsequently developed the disease.

27 Oct 2009

African Americans face higher risk of colorectal cancer

African Americans are at significantly higher risk of developing colorectal cancer, and being diagnosed with the disease at a later stage, than other ethnic groups. That's the finding of a paper being presented at the annual meeting of the American College of Gastroenterology in San Diego.

26 Oct 2009

Researchers elucidate the effect of nutritional parameters in long-term PPI therapy

Gastroesophageal reflux disease (GERD) is the most common esophageal disorder, and frequently encountered in the primary care setting. Accumulating evidence has confirmed the excellent efficacy and safety of proton pump inhibitor (PPI) therapy in patients with all grades of GERD, making these agents the mainstay of treatment.

24 Oct 2009

Emodin raises hope for treatment of fibrotic liver diseases

In the last decade, advances in the understanding of genes promoting hepatic stellate cell (HSC) activation are impressive. However, there are few breakthroughs in therapeutic intervention of hepatic fibrogenesis. Efficient and well-tolerated antifibrotic drugs are lacking and current treatment of hepatic fibrosis is limited to withdrawal of the noxious agent. Research identifying innocuous antifibrotic agents is of high priority and urgently needed.

24 Oct 2009

Researchers find link between hepatic steatosis and carotid lesions

Nonalcoholic fatty liver disease (NAFLD) is often caused by abdominal obesity, which is also one of the main causes of insulin resistance and metabolic syndrome. The latter, in turn, is an important cardiovascular risk factor, and has been found to be associated with the presence of carotid atherosclerotic lesions.

24 Oct 2009

Researchers question the necessity of duodenal biopsy for celiac disease diagnosis

Duodenal biopsy remains the gold standard for celiac disease (CD) diagnosis. However, it has several pitfalls and requires an invasive procedure in children. In the past few years, a more prominent role for a definitive diagnosis based solely on serology has been proposed. The predictive value of high levels of anti-tissue transglutaminase (tTG) antibodies has also been reported in retrospective CD cohorts.

24 Oct 2009

2009 Inspiration Gala raises $1.27 million for BC Cancer Foundation

The 2009 Inspiration Gala raised $1.27 million for the BC Cancer Foundation and colorectal cancer research at the BC Cancer Agency last night, as nearly 400 guests dined and donated during the emotion-filled, sold-out event.

24 Oct 2009

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.

23 Oct 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Perioperative oral dietary supplements before elective surgery offers no functional benefit

Study: Short-term use of COX-2 inhibitors may help prevent gastric cancer

Lifestyle and genetic factors are considered to play a major role in "Asian paradox"

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Data from Phase II clinical trial of NKTR-118 presented

Eli Lilly receives access to GeneNews' osteoarthritis genomic biomarker program

Studies highlight race- and gender-specific disparities in gastrointestinal disease

Colonoscopy recommended as primary screening method for colorectal cancer, researchers report

Some colonoscopic technologies better at improving detection of adenomas

Comprehensive, risk-based screening guidelines for breast, cervical and colorectal cancers

Clinical trial helps improve prognosis and changes the standard of care for patients with colorectal cancer

African Americans face higher risk of colorectal cancer

Researchers elucidate the effect of nutritional parameters in long-term PPI therapy

Emodin raises hope for treatment of fibrotic liver diseases

Researchers find link between hepatic steatosis and carotid lesions

Researchers question the necessity of duodenal biopsy for celiac disease diagnosis

2009 Inspiration Gala raises $1.27 million for BC Cancer Foundation

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Celgene announces fiscal 2009 third-quarter results

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in